Safety

News

Study links Ozempic/Wegovy to sight-threatening disorder

Shares in Novo Nordisk and Eli Lilly have been under pressure after a study emerged suggesting that people taking a GLP-1 agonist had an elevated risk of a rare but serious eye condition.

News

NWEH says module cuts side effect reporting burden in trials

Monitoring patient safety is of the utmost importance when running a clinical trial, but recording and reporting side effects can be labour-intensive and costly.

News

Study finds low secondary cancer risk with CAR-Ts

There’s no doubt that CAR-T therapies have transformed the treatment of many blood cancers, but a risk of secondary malignancies has cast a pall over the class.

R&D

Advancing innovation in life sciences R&D and Quality: Towar...

This year’s Veeva R&D and Quality Summit saw full-house attendance at the Marriott Auditorium Hotel in Madrid.

News

Pfizer pauses DMD gene therapy trial after boy’s death

The death of a young boy with Duchenne muscular dystrophy (DMD) who was treated with Pfizer’s experimental gene therapy in a phase 2 trial has prompted the company to paus

News

EMA finds no suicide risk with GLP-1 diabetes, obesity drugs

There is no evidence of an increased risk of suicidal or self-injurious thoughts and actions with GLP-1 agonists used to treat diabetes and obesity, according to the EU me

Study links Ozempic/Wegovy to sight-threatening disorder

NWEH says module cuts side effect reporting burden in trials

Study finds low secondary cancer risk with CAR-Ts

Advancing innovation in life sciences R&D and Quality: Towar...

Pfizer pauses DMD gene therapy trial after boy’s death

EMA finds no suicide risk with GLP-1 diabetes, obesity drugs

Remepy's hybrid Parkinson's therapy poised for phase 3

Discover a new era of healthcare panel engagement: Grounded ...

Safety

Editor's Picks